Search

Displaying results 3701 - 3710 of 10000 in total
  1. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

    Categories: Heterocyclic Compounds, 2-Ring
  2. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance

  3. Drug

    Isoflavone

    go.drugbank.com/drugs/DB12007
    ApprovedInvestigationalWithdrawn

    Soybean is an exceptionally rich source of dietary isoflavones, where the average isoflavone content is 1-2 mg/gram [A33103]. … Isoflavone is a soy phytoestrogen and a biologically active component of several agriculturally important legumes such as soy, peanut, green peas, chick peas and alfalfa [A33103].

    Mixtures: ISOFEM ® TABLETA RECUBIERTACategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  4. Drug

    Tridolgosir

    go.drugbank.com/drugs/DB02034
    Experimental

    An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.

  5. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. … Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1).

  6. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  7. Drug

    XMT-1001

    go.drugbank.com/drugs/DB06069
    Investigational

    XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. … It is a water-soluble macromolecular conjugate of camptothecin (CPT).

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    AG-702

    go.drugbank.com/drugs/DB05836
    Experimental

    This drug is developed by antigenics for the treatment of genital herpes infection and is under phase I of clinical trial. … AG-702 is a recombinant human heat shock protein also known as stress protein.

  9. Drug

    Lemuteporfin

    go.drugbank.com/drugs/DB04980
    Investigational

    Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More Rings
  10. Drug

    FavId

    go.drugbank.com/drugs/DB05249
    Investigational

    FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.